Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Myelofibrosis Clinical Trial

Official title:

Pilot Safety and Feasibility Trial of Mycophenolate and Sirolimus for Prevention of GVHD in Mismatched Unrelated and Related Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02728700
• Other study ID #: IRB-34973
• Secondary ID: NCI-2016-00387PE
• Status: Terminated
• Phase: Phase 1
• Start date: February 2016
• Est. completion date: July 2018

Study information

• Verified date: August 2018
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot phase I/II trial studies the side effects and how well sirolimus and mycophenolate mofetil work in preventing graft versus host disease (GvHD) in patients with hematologic malignancies undergoing hematopoietic stem cell transplant (HSCT). Biological therapies, such as sirolimus and mycophenolate mofetil, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Giving sirolimus and mycophenolate mofetil after hematopoietic stem cell transplant may be better in preventing graft-versus-host disease.

Description:

PRIMARY OBJECTIVES:

I. Evaluate the safety and feasibility of administering sirolimus and mycophenolate mofetil (MMF) as prophylaxis of grade III-IV acute graft versus host disease (aGvHD) in patients undergoing mismatched unrelated and related donor hematopoietic stem cell transplant (HSCT).

OUTLINE:

Patients receive sirolimus orally (PO) starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil intravenously (IV) or PO three times a day (TID) on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at days 30, 60, 100, 180, 270, and 365, and then yearly thereafter.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: July 2018
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 30 Years

Eligibility

Inclusion Criteria:

• Subjects must have one of the following disease categories:

• Acute myeloid leukemia (AML) beyond 2nd remission or relapsed/refractory disease

• Acute lymphoblastic leukemia (ALL) beyond 2nd remission or relapsed/refractory disease

• Chronic myeloid leukemia (CML) beyond 2nd chronic phase or in blast crises

• Myelodysplastic syndrome (MDS)

• Myeloproliferative disorders including myeloid metaplasia and myelofibrosis

• High risk non-Hodgkin's lymphoma (NHL) in first remission

• Relapsed or refractory NHL

• Hodgkin's lymphoma (HL) beyond first remission

• Performance status by Karnofsky of >= 70% or Lansky > 70% for patients < 16 years of age

• Human leukocyte antigen (HLA) mismatched related or unrelated donor identified 8/10 or 9/10

• Willingness to take oral medications during the transplantation period

• Willingness and ability to sign a written informed consent (assent if applicable)

Exclusion Criteria:

• Prior myeloablative allogeneic or autologous HSCT

• Human immunodeficiency virus (HIV) infection

• Pregnant or lactating females

• Evidence of uncontrolled active infection

• Down syndrome

• Serum creatinine (CR) < 1.5mg/dl or 24 hour CR clearance < 50 ml/min

• Direct bilirubin > 2 x upper limit of normal (ULN)

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN

• Carbon monoxide diffusing capability test (DLCO) > 60% predicted and in children- room air oxygen saturation > 92%

• Left ventricular ejection fraction < 45% and in children-shortening fraction < 26%

• Fasting cholesterol > 300 mg/dl or triglycerides > 300 while on lipid lowering agents

• Patients who have received an investigational drug within 30 days of enrollment in study

• Patients with prior malignancies except basal cell carcinoma or treated carcinoma in-situ; cancer treated with curative intent > 5 years will be allowed; cancer treatment with curative intent =< 5 years will not be allowed

Related Conditions & MeSH terms

• Adult Hodgkin Lymphoma
• Adult Myelodysplastic Syndrome
• Blast Crisis
• Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Childhood Hodgkin Lymphoma
• Childhood Myelodysplastic Syndrome
• Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Hodgkin Disease
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Leukemia, Myeloid, Chronic-Phase
• Lymphoma
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Myelofibrosis
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia
• Primary Myelofibrosis
• Recurrent Adult Acute Lymphoblastic Leukemia
• Recurrent Adult Acute Myeloid Leukemia
• Recurrent Adult Non-Hodgkin Lymphoma
• Recurrent Childhood Acute Lymphoblastic Leukemia
• Recurrent Childhood Acute Myeloid Leukemia
• Recurrent Childhood Non-Hodgkin Lymphoma
• Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Refractory Non-Hodgkin Lymphoma
• Syndrome

Intervention

Procedure:
• Allogeneic Hematopoietic Stem Cell Transplantation
Undergo HSCT

Other:
• Laboratory Biomarker Analysis
Correlative studies

Drug:
• Mycophenolate Mofetil
Given IV
• Sirolimus
Given PO

Locations

Country	Name	City	State
United States	Stanford University, School of Medicine	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of acute GvHD grade 3 & 4, according to the Glucksberg staging criteria	Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum.	Up to 60 days post-transplant
Primary	Incidence of acute GvHD grade 3 & 4, according to the Glucksberg staging criteria	Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum.	Up to 100 days post-transplant
Secondary	Incidence of thrombotic microangiopathy defined according to the bone marrow transplant clinical trials network toxicity committee	Defined as: red blood cell fragmentation and at least two schistocytes per high-power field on peripheral smear; concurrent increased serum lactate dehydrogenase measurement above institutional baseline; concurrent doubling of serum creatinine or 50% increase in creatinine clearance from baseline and/or neurological dysfunction without other explanations; and negative direct and indirect Coombs. Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum.	Up to 100 days
Secondary	Incidence of venous-occlusive disease (VOD) using Modified Seattle Criteria	Severe VOD will be considered a dose limiting toxicity. Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum.	Up to 100 days
Secondary	Severity of mucositis determined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03	Grade III and IV will be considered dose limiting toxicities. Statistical analysis results will be reported using summary tables, figures, and data listings. Categorical variables will be summarized by numbers and percentages of subjects in corresponding categories.	Up to 100 days
Secondary	Time to neutrophil engraftment defined as first of 3 consecutive days with the absolute neutrophil count is > 500/ul in the peripheral blood	Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum.	Baseline to up to 100 days
Secondary	Time to platelet engraftment defined as the first day of a minimum of three consecutive measurements on different days when platelet count > 50,000/mm^3 and patient is transfusion-independent for a minimum of 7 days	Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum.	Baseline to up to 100 days